Trial Profile
A 3-day proof-of-concept study assessing multiple doses of IDX 719 in treatment-naive patients with genotype 1, 2, 3 or 4 hepatitis C virus infections.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2013
Price :
$35
*
At a glance
- Drugs Samatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2013 Data will be presented during Asian Pacific Association for the Study of the Liver (APASL) Liver Week 2013, according to an Idenix Pharmaceuticals media release.
- 24 Apr 2013 Data was presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013; Abstract No. 1209), according to an Idenix Pharmaceuticals media release.
- 09 Apr 2013 Data from this trial will be presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) according to an Idenix media release.